Novo Nordisk: has proposed acquisition of Belgium's Ablynx
(CercleFinance.com) - Novo Nordisk has offered to acquire Ablynx for approximately 2.
6 billion euros, but so far the Belgian biopharmaceutical company has declined to engage in any discussions, the Danish drugmaker said on Monday.
Novo Nordisk confirmed today that it made a proposal on 22 December to buy Ablynx for 30.50 euros per share in cash, consisting of 28.00 euros upfront and 2.50 euros in contingent value rights (CVR).
This offer - which represents a premium of 44% over Ablynx's share price as of last Friday - is the second proposal that Novo Nordisk has made to Ablynx's board of directors, the Danish firm said.
Novo Nordisk said it intends to combine Ablynx's leading asset caplacizumab, for the treatment of rare bleeding disorders, with its own haematology franchise, making Ablynx a global antibody centre-of-excellence within Novo Nordisk.
After Novo Nordisk's offers were both refused by Ablynx's board, the group now encourages Ablynx to engage in a negotiated transaction "for the benefit of all stakeholders."
Ablynx shares were suspended from trading on Euronext Brussels on Monday. Meanwhile, Novo Nordisk shares listed on Nasdaq Nordic were trading up 0.1% at 338.8 Danish kronor.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
6 billion euros, but so far the Belgian biopharmaceutical company has declined to engage in any discussions, the Danish drugmaker said on Monday.
Novo Nordisk confirmed today that it made a proposal on 22 December to buy Ablynx for 30.50 euros per share in cash, consisting of 28.00 euros upfront and 2.50 euros in contingent value rights (CVR).
This offer - which represents a premium of 44% over Ablynx's share price as of last Friday - is the second proposal that Novo Nordisk has made to Ablynx's board of directors, the Danish firm said.
Novo Nordisk said it intends to combine Ablynx's leading asset caplacizumab, for the treatment of rare bleeding disorders, with its own haematology franchise, making Ablynx a global antibody centre-of-excellence within Novo Nordisk.
After Novo Nordisk's offers were both refused by Ablynx's board, the group now encourages Ablynx to engage in a negotiated transaction "for the benefit of all stakeholders."
Ablynx shares were suspended from trading on Euronext Brussels on Monday. Meanwhile, Novo Nordisk shares listed on Nasdaq Nordic were trading up 0.1% at 338.8 Danish kronor.
Copyright (c) 2018 CercleFinance.com. All rights reserved.